Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 7076 - 7100 of 8235 in total
Efungumab is under investigation in clinical trial NCT00217815 (Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer).
Investigational
Matched Description: … Efungumab is under investigation in clinical trial NCT00217815 (Preliminary Study of Mycograb and Docetaxel …
TBA-7371 is under investigation in clinical trial NCT04176250 (Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis).
Investigational
Matched Description: … TBA-7371 is under investigation in clinical trial NCT04176250 (Early Bactericidal Activity of TBA-7371 …
Alomfilimab is under investigation in clinical trial NCT03829501 (Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer).
Investigational
Matched Description: … Alomfilimab is under investigation in clinical trial NCT03829501 (Safety and Efficacy of KY1044 and Atezolizumab …
OPC1 is an oligodendrocyte progenitor cell therapy being investigated for the treatment of acute spinal cord injury.
Investigational
Matched Description: … OPC1 is an oligodendrocyte progenitor cell therapy being investigated for the treatment of acute spinal …
FCX-013 consists of human dermal fibroblasts genetically modified with a lentiviral vector expressing metalloproteinase-1 (MMP-1).
Investigational
Matched Description: … FCX-013 consists of human dermal fibroblasts genetically modified with a lentiviral vector expressing …
MBX-2109 is a long-acting parathyroid hormone peptide prodrug under investigation for the treatment of hyperparathyroidism.
Investigational
Matched Description: … MBX-2109 is a long-acting parathyroid hormone peptide prodrug under investigation for the treatment of
Rovaleucel is an EBV-specific autologous T-cell therapy under investigation for the treatment of EBV-positive cancers.
Investigational
Matched Description: … Rovaleucel is an EBV-specific autologous T-cell therapy under investigation for the treatment of EBV-positive …
Zigakibart is under investigation in clinical trial NCT05852938 (A Study of BION-1301 in Adults With Iga Nephropathy).
Investigational
Matched Description: … Zigakibart is under investigation in clinical trial NCT05852938 (A Study of BION-1301 in Adults With …
ASTX-029 is under investigation in clinical trial NCT03520075 (Study of ASTX029 in Subjects With Advanced Solid Tumors).
Investigational
Matched Description: … ASTX-029 is under investigation in clinical trial NCT03520075 (Study of ASTX029 in Subjects With Advanced …
Stapokibart is under investigation in clinical trial NCT06424470 (Study on the Treatment of Prurigo Nodularis With Stapokibart Injection).
Investigational
Matched Description: … Stapokibart is under investigation in clinical trial NCT06424470 (Study on the Treatment of Prurigo Nodularis …
Elimusertib is under investigation in clinical trial NCT05071209 (Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors).
Investigational
Matched Description: … Elimusertib is under investigation in clinical trial NCT05071209 (Elimusertib for the Treatment of Relapsed …
Pleconaril is an antiviral drug from viral capsid inhibitor class, manufactured by Schering-Plough and intended for the prevention of acute asthma exacerbations and common cold symptoms in asthmatic patients who have had exposure to picornavirus. It acts by inhibiting viral replication. The use of pleconaril has not gained approval by...
Investigational
Matched Description: … The use of pleconaril has not gained approval by the U.S. ... from _viral capsid inhibitor_ class, manufactured by _Schering-Plough_ and intended for the prevention of
Fecal microbiota transplantation (FMT) is effective in enhancing the gut microbiota of patients experiencing a high range of disease states, including Clostridioides difficile (C. diff) infection, Crohn’s disease, and ulcerative colitis. Washed microbiota preparation (WMT) involves a method wherein FMT is used, but the preparation undergoes microfiltration through an automatic...
Investigational
Matched Description: … Fecal microbiota transplantation (FMT) is effective in enhancing the gut microbiota of patients experiencing ... a high range of disease states, including Clostridioides difficile (C. diff) infection, Crohn’s disease …
TPMPA ((1,2,5,6-tetrahydropyridine-4-yl)methylphosphinic acid) is a selective antagonist of GABAC receptors (also known as GABA-ρ or GABAA-ρ receptors). GABAC receptors are found primarily in the retina, although they may be present in other tissues, including the hippocampus, spinal cord, superior colliculus, pituitary and the gut.[A245308,A245313] TPMPA is used as a pharmacological...
Experimental
Matched Description: … TPMPA ((1,2,5,6-tetrahydropyridine-4-yl)methylphosphinic acid) is a selective antagonist of GABA ... [A245308,A245313] TPMPA is used as a pharmacological probe for the investigation of GABAC
Piclamilast (RP-73,401), is a selective PDE4 inhibitor comparable to other PDE4 inhibitors for its anti-inflammatory effects. It has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma. The structure for piclamilast was first elucidated in a 1995 European patent...
Experimental
Matched Description: … It has been investigated for its applications to the treatment of conditions such as chronic obstructive ... first elucidated in a 1995 European patent application and exhibits the structural functionalities of
Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH). The US FDA granted...
Investigational
Matched Description: … The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated ... injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of
Velafermin was a novel investigational protein therapeutic, also known as fibroblast growth factor-20 (FGF-20), which promotes both epithelial and mesenchymal cell proliferation in vitro and has demonstrated activity in multiple animal models. Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis by fostering the...
Investigational
Matched Description: … by fostering the regeneration and repair of the cells lining the gastrointestinal tract. ... Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis …
The 3-O-valine ester prodrug of the nucleoside analog 2'-C-methylcytidine with anti-hepatitis C virus (HCV) activity. Upon administration, valopicitabine is converted into 2'-C-methylcytidine; upon phosphorylation into its 5-triphosphate form, this metabolite inhibits viral RNA chain elongation and viral RNA-dependent RNA polymerase activity. This blocks viral production of HCV RNA and thus...
Experimental
Matched Description: … This blocks viral production of HCV RNA and thus viral replication. [from NCI] ... The 3-O-valine ester prodrug of the nucleoside analog 2'-C-methylcytidine with anti-hepatitis C virus …
"Catuaba" is a general term for a medicinal infusion created by the bark of plants belonging to the Erythroxylum genus, though this name is also applied to infusions of plants belonging to other genera. The infusion is thought to carry stimulant and aphrodisiac effects, and catuaba made specifically with Trichilia...
Experimental
Matched Description: … "Catuaba" is a general term for a medicinal infusion created by the bark of plants belonging to the _ ... Erythroxylum_ genus, though this name is also applied to infusions of plants belonging to other genera …
The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body. As of June 2020, the company received regulatory approval from German and Belgian Authorities...
Investigational
Matched Description: … Phase 1 clinical trials of this vaccine (NCT04449276). ... As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence …
Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential treatment of visceral leishmaniasis.
Investigational
Matched Description: … Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential treatment of
A vaccine containing a heat-killed recombinant Saccharomyces cerevisiae yeast transfected with mutated forms of Ras, an oncogene frequently found in solid tumors, with potential immunostimulant and antitumor activity.
Investigational
Matched Description: … containing a heat-killed recombinant Saccharomyces cerevisiae yeast transfected with mutated forms of
EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity.
Investigational
Matched Description: … EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin …
BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM). So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.
Experimental
Matched Description: … So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause. …
Fluoromisonidazole F-18 is under investigation in clinical trial NCT01507428 (Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer).
Investigational
Matched Description: … Fluoromisonidazole F-18 is under investigation in clinical trial NCT01507428 (Study of Positron Emission …
Displaying drugs 7076 - 7100 of 8235 in total